Search

Your search keyword '"Ming Mo Hou"' showing total 2 results
Start Over Author "Ming Mo Hou" Publisher springer nature
2 results on '"Ming Mo Hou"'

1. Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma.

Author

Ming-Mo Hou, Jia-Juan Hsieh, Nai-Jen Chang, Hsuan-Ying Huang, Hung-Ming Wang, Cheng-Keng Chuang, Todd Hsu, and John Wen-Cheng Chang

Subjects
*CANCER treatment, *RENAL cell carcinoma, *CANCER patients, *CELL proliferation, *DIAGNOSTIC imaging, *NEOVASCULARIZATION
Abstract

Sorafenib, a multikinase inhibitor of tumour-cell proliferation and angiogenesis, has been shown to have a role in the treatment of metastatic renal cell carcinoma (RCC). Xpl 1 translocation carcinoma is a rare subtype of RCC. We report an 18-year-old male patient with metastatic Xpll trans- location RCC who was responsive to sorafenib treatment. Six weeks after commencement of treatment with sorafenib, a CT scan of the patient showed increased central necrosis of the kidney mass and para-aortic lymph nodes as well as regression of the lung and pleural masses. The patient had a progression-free survival of 12 months, and overall survival of 15 months. The most severe adverse effects were gradc 3 dermatitis and grade 3 anaemia. This case has demonstrated for the first time that sorafenib is active against Xpl 1 translocation RCC. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

2. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience

Author

Vivek Subbiah, Pedro T. Ramirez, Filip Janku, Funda Meric-Bernstam, Lois M. Ramondetta, Ralph Zinner, Naiyi Shi, Apostolia Maria Tsimberidou, Jing Gong, Jennifer J. Wheler, Aung Naing, Siqing Fu, Sarina Anne Piha-Paul, Ming-Mo Hou, David S. Hong, and Karen H. Lu

Subjects
Vaginal cancer, Oncology, medicine.medical_specialty, Vulvar cancer, business.industry, Research, Molecular analysis, Medical record, Retrospective cohort study, Disease, medicine.disease, Clinical trial, Phase I trial, Internal medicine, Overall survival, Medicine, business, Body mass index
Abstract

Background Early-stage vaginal and vulvar cancer can be cured. But outcomes of patients with metastatic disease are poor. Thus, new therapeutic strategies are urgently required. Methods In this retrospective study, we analyzed the clinical outcomes of consecutive patients with metastatic vaginal or vulvar cancer who were referred to a phase I trial clinic between January 2006 and December 2013. Demographic and clinical data were obtained from patients’ electronic medical records. Results Patients with metastatic vaginal (n = 16) and vulvar (n = 20) cancer who were referred for phase I trial therapy had median overall survival durations of 6.2 and 4.6 months, respectively. Among those who underwent therapy (n = 27), one experienced a partial response and three experienced stable disease for at least 6 months. Patients with a body mass index ≥30 had a significantly longer median overall survival duration than did those with a body mass index

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results